Efficacy and Safety of Mefloquine, Artesunate, Mefloquine‐Artesunate, and Praziquantel against<i>Schistosoma haematobium</i>: Randomized, Exploratory Open‐Label Trial

Keiser, Jennifer; A. N’Guessan, Nicaise; Daho Adoubryn, Koffi; D. Silué, Kigbafori; Vounatsou, Penelope; Hatz, Christoph; Utzinger, Jürg; K. N’Goran, Eliézer

doi:10.1086/651682

Public

Efficacy and Safety of Mefloquine, Artesunate, Mefloquine‐Artesunate, and Praziquantel againstSchistosoma haematobium: Randomized, Exploratory Open‐Label Trial

Published in Clinical Infectious Diseases • Mar 29, 2010

Authors:

Jennifer Keiser

Nicaise A. N’Guessan

Koffi Daho Adoubryn

Abstract

BACKGROUND: Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed. METHODS: We conducted a randomized, exploratory open-label trial to assess the effi...

Subject

Mefloquine

Artesunate

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!